Literature DB >> 18089709

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.

Florence Chan1, Chongbo Sun, Meg Perumal, Quang-De Nguyen, Vassilios Bavetsias, Edward McDonald, Vanessa Martins, Nicola E Wilsher, Florence I Raynaud, Melanie Valenti, Sue Eccles, Robert Te Poele, Paul Workman, Eric O Aboagye, Spiros Linardopoulos.   

Abstract

The Aurora family of serine/threonine kinases is important for the regulation of centrosome maturation, chromosome segregation, and cytokinesis during mitosis. Overexpression of Aurora kinases in mammalian cells leads to genetic instability and transformation. Increased levels of Aurora kinases have also been linked to a broad range of human tumors. Here, we describe the properties of CCT129202, a representative of a structurally novel series of imidazopyridine small-molecule inhibitors of Aurora kinase activity. This compound showed high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines. CCT129202 causes the accumulation of human tumor cells with >or=4N DNA content, leading to apoptosis. CCT120202-treated human tumor cells showed a delay in mitosis, abrogation of nocodazole-induced mitotic arrest, and spindle defects. Growth of HCT116 xenografts in nude mice was inhibited after i.p. administration of CCT129202. We show that p21, the cyclin-dependent kinase inhibitor, is induced by CCT129202. Up-regulation of p21 by CCT129202 in HCT116 cells led to Rb hypophosphorylation and E2F inhibition, contributing to a decrease in thymidine kinase 1 transcription. This has facilitated the use of 3'-deoxy-3'[(18)F]fluorothymidine-positron emission tomography to measure noninvasively the biological activity of the Aurora kinase inhibitor CCT129202 in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089709     DOI: 10.1158/1535-7163.MCT-07-2156

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  23 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Authors:  Jayasree S Nair; Alan L Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

Review 3.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.

Authors:  Maxim A Moroz; Tatiana Kochetkov; Shangde Cai; Jiyuan Wu; Mikhail Shamis; Jayasree Nair; Elisa de Stanchina; Inna Serganova; Gary K Schwartz; Debabrata Banerjee; Joseph R Bertino; Ronald G Blasberg
Journal:  Clin Cancer Res       Date:  2011-01-18       Impact factor: 12.531

Review 5.  Aurora kinase inhibitors--rising stars in cancer therapeutics?

Authors:  Altaf A Dar; Laura W Goff; Shahana Majid; Jordan Berlin; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

6.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

7.  A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

Authors:  Roger B Cohen; Suzanne F Jones; Charu Aggarwal; Margaret von Mehren; Jonathan Cheng; David R Spigel; F Anthony Greco; Mariangela Mariani; Maurizio Rocchetti; Roberta Ceruti; Silvia Comis; Bernard Laffranchi; Jurgen Moll; Howard A Burris
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

Review 8.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

Review 9.  Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

Authors:  Mette Munk Jensen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

10.  The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

Authors:  Amir Faisal; Lynsey Vaughan; Vassilios Bavetsias; Chongbo Sun; Butrus Atrash; Sian Avery; Yann Jamin; Simon P Robinson; Paul Workman; Julian Blagg; Florence I Raynaud; Suzanne A Eccles; Louis Chesler; Spiros Linardopoulos
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.